Biocept Announces Collaboration with the OHSU Knight Cancer Institute to Increase Clinical Adoption of Liquid Biopsy Testing and to Co-Develop Additional Assay Platform Capabilities
"We are pleased to enter into this collaboration with
The OHSU
"Our agreement with OHSU is a major milestone for
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of cancer patients, our ability to co-develop additional
liquid biopsy assay technologies and platform capabilities, liquid biopsy transforming the standard of care for cancer treatment, our ability to solidify our leadership position in the liquid biopsy market, and our ability to increase the clinical adoption of our testing services, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-announces-collaboration-with-the-ohsu-knight-cancer-institute-to-increase-clinical-adoption-of-liquid-biopsy-testing-and-to-co-develop-additional-assay-platform-capabilities-300433227.html
SOURCE
News Provided by Acquire Media